CzbnAuto® Autologous Kidney Stem Cells
Product Specifications
| ID | Product Specifications | Product Name |
|---|---|---|
| Czbn-ASC009 | 0.1-2×10⁸ | CzbnAuto® Autologous Kidney Stem Cells |
Cell Properties
Kidney tissue-specific stem and progenitor cells.
Core Features
Renal tubular epithelial repair
Differentiate into proximal and distal tubular epithelial cells to replace damaged tubular epithelium from ischemia or toxins, restoring tubular reabsorption and secretion functions.
Kidney microenvironment regulation
Secretes cytokines to reduce kidney inflammation, inhibit interstitial fibroblast activation, and delay renal interstitial fibrosis.
Transform Application Research Directions
The following content is based on the biological characteristics of autologous kidney stem cells and publicly available research, intended for educational purposes only and not as medical advice. Related clinical applications must be conducted in licensed healthcare facilities in compliance with applicable laws and regulations.
Acute Kidney Injury (AKI)
Research focuses on promoting repair of renal tubular epithelial cells, reducing kidney inflammation and injury, improving renal function, and exploring the potential to reduce dialysis dependence in patients with AKI.
Chronic Kidney Disease (CKD) and End-Stage Renal Disease (ESRD)
Explore the feasibility of partially replacing dialysis and kidney transplantation by repairing renal fibrosis, slowing renal function decline, improving eGFR and serum creatinine levels, and providing new intervention options for patients with end-stage kidney disease.
Diabetic Nephropathy (DN)
Research to protect glomerular epithelial cells, reduce proteinuria, and slow the progression of diabetic nephropathy.
Other Kidney Diseases
Demonstrates potential for repair and symptom relief in interventions for polycystic kidney disease (inhibiting cyst growth), nephrotic syndrome (reducing proteinuria and improving renal function), and glomerulonephritis.
Why Choose Chunzhu: The Century-Long Life Bank
Third-generation iPSC small-molecule transdifferentiation technology derived from Nobel Prize-winning research
- No gene editing involved, ensuring greater safety.
- Preparation of autologous kidney stem cells via blood cell transdifferentiation
- Capable of renal lineage-directed differentiation; suited for kidney health management.
Six Core Advantages
- Draw 80-150 ml of blood; complete library construction within 6-10 days.
- Autologous cell source with low risk of immune rejection and no gene editing involved.
- Store for all ages; produce functional cells on demand
Empowering the Human Genetic Resources Platform
- Platform inbound management, end-to-end sample monitoring and traceability
- Companion AI health simulation and clinical reference plans
Cooperative Consortium of the Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences
- Sync cutting-edge research findings
- Accelerate technology iteration and clinical research advancement
End-to-end workflow: Preparation · Storage · Tertiary Hospital Clinical Integration
- Beyond just storing cells, we enable seamless access and usage.
- Support future clinical translation and implementation
Three steps to storage
Blood Collection and Sampling
80-150ml blood sample collection
GMP Laboratory Library Preparation
Cell preparation and library construction completed in 6-10 days
-196°C Liquid Nitrogen Long-Term Deep-Freeze Storage
Long-term storage and on-demand production of targeted functional cells
This page provides educational information on stem cell science and our company's R&D directions. It does not constitute medical advice or a guarantee of treatment outcomes. For specific applications, please follow the guidance of qualified healthcare professionals.